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Abstract
Background: Osteoarthritis (OA) is described by an imbalance between anabolic and catabolic processes in
the affected joint. This dysregulation of metabolism affects not only chondrocytes within cartilage tissue but
also the cells of the synovial membrane across the border of the joint. An important factor in OA is the low viscosity of
the synovial fluid. High-molecular-weight hyaluronic acid (HA) can be used to increase the viscosity and also
reduce inflammatory processes. The purpose was to establish an in vitro inflammation model and to evaluate the
effects of high-molecular-weight HA in a co-cultivation inflammation model of osteoarthritic chondrocytes and M1
macrophages.
Methods: For the establishment of the inflammation model THP-1 cells were, at first, differentiated to M0
macrophages and then activated to the M1 subtype after 5 days of resting period. Surface markers, cytokine release,
and gene expression, were analyzed to examine the successful differentiation. In the inflammation model, the defined
M1 macrophages were co-cultivated with osteoarthritic chondrocytes for 2 days, with and without the
addition of 10 % HA and further analyzed for chondrogenic gene expression markers and the release of
cytokines in the supernatant.
Results: The differentiation and activation process was successful as M1 macrophages expressed higher levels
of pro-inflammatory cytokines and specific genes. Similarly, the surface marker CD14 was significantly decreased
compared to M0 macrophages. For the co-culture system, the analysis of gene expression showed that HA increased
the expression of cartilage-specific genes while catabolic-encoding genes exhibited lower expression levels than the
control group. This positive effect of HA was also demonstrated by the measurement of pro-inflammatory cytokines, as
their level decreased.
Conclusion: Our study implies that high-molecular-weight HA has a chondroprotective effect in the present
co-cultivation inflammation model, as it decreases pro-inflammatory cytokines and increases anabolic factors.
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Background
The development of osteoarthritis (OA) primarily oc-
curs in response to mechanical stress associated with
obesity, trauma or genetic predisposition [1–3]. OA pa-
tients suffer from pain, disability and a dramatic reduction
in quality of life. During degenerative processes in OA, a
massive destruction of joint tissue, including bone, cartil-
age, and synovial membrane occurs and leads to aseptic
inflammation that further prolongs the joint disease. Car-
tilage breakdown is then associated with the formation of
osteophytes, subsequent degeneration of menisci and liga-
ments as well as inflammation of the synovium that is
transformed into a fibrotic tissue with pannus formation
[1, 2, 4]. Synovial inflammation or synovitis plays a signifi-
cant role in the progression of OA and is accompanied by
hyperplasia and infiltration of macrophages and lympho-
cytes [5, 6]. These cells, as well as chondrocytes, produce
soluble inflammatory mediators like IL-1β, IL-6, and
TNF-α, which stimulate the production of degradative en-
zymes (e.g. MMPs, aggrecanases), that are often found
in increased levels in OA synovial fluids post-injury
in joint tissues [7–9].
Treatment modalities for OA include non-
pharmacological (e.g. physiotherapy), pharmacological
(e.g. hormones) or intra-articular (e.g. injection of
hyaluronic acid) therapies [1, 2]. Disease-modifying
anti-rheumatic drugs (DMARDs) or non-steroidal
anti-inflammatory drugs (NSAIDs), which are used in
OA are inadequate due to poor and patient-specific
efficacy. Although DMARDs and NSAIDs decrease
pain and inflammation, they often fail to inhibit car-
tilage degradation. Furthermore, efficacy is lost over
time and so constantly increasing doses are required
to ensure an effect, which often augments their tox-
icity and other side effects. Corticosteroids, currently
available as alternative treatment options are highly
effective to reduce inflammation and pain by inhib-
ition of the cytokine signaling mediators, but their
adverse effects like osteoporosis or immunosuppres-
sion are highly problematic [10].
The mentioned therapies have been proved to re-
verse the symptoms in most cases. However, the po-
tential to stop degeneration process of the cartilage
and in promoting the reconstruction of the tissue is
limited. Therefore, the development of new therapies
with disease-modulating aspects, like the reduction of
pro-inflammatory cytokines and degrading enzymes
play a central role in osteoarthritis research with a
substantial increase in cost effectiveness [1, 2]. In this
context, hyaluronic acid (HA), used as an intra-
articular treatment option, is a conventional therapy
to replace the synovial fluid that has lost its viscoelas-
tic properties. In cases of inflammation and tissue in-
jury, HA plays a central role, as it can function as a
pro- and anti-inflammatory molecule. This fact highly de-
pends on its molecular weight, microenvironment and the
availability of specific binding partners [11–13].
Despite strong potentials of HA in tissue engineering,
its precise role in anti-inflammatory responses on OA
chondrocytes is not well explored.
In this study, we evaluated the influence of pro-in-
flammatory M1 macrophages on osteoarthritic chondro-
cytes in a newly established in vitro co-culture system and
assess the chondroprotective effect of high-molecular-
weight HA against an inflammatory response.
Methods
Hyaluronic acid
The high-molecular-weight HA is highly purified and
has a molecular weight of 1600 kDA. It was produced by
Croma Pharma GmbH by fermentation process and the
raw material was further dissolved in PBS (phosphate
buffered saline). The product is commercially available
and widely used in clinical practice.
Cell culture and differentiation of THP-1 monocytes to
macrophages
The THP-1 monocytic cell line was obtained from
ATCC. The cells were cultured at a density of 0.2 – 1.0
× 106 cells/ml in culture medium (GIBCO® DMEM/F12
GlutaMAX ™-I, Invitrogen, LifeTech Austria, Vienna,
Austria) with antibiotics (penicillin 200 U/ml; strepto-
mycin 0.2 mg/ml and Amphotericin B 2.5 μg/ml (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany)). For the
establishment of the inflammation model, THP-1 cells
were seeded into 175 cm2 cell culture flasks (2.3 x 106
cells/flask) and differentiated to macrophages for 3 days
by adding 100 nM phorbol-12-myristate 13-acetate
(PMA) (Sigma-Aldrich Chemie GmbH, Steinheim,
Germany). After the initial stimulation, the differenti-
ation of PMA treated THP-1 cells was extended by re-
moving the PMA containing media and incubating the
cells in fresh culture medium for further 5 days.
Differentiation to M1 macrophages
After a total of 8 days (3 days PMA, 5 days resting), the ob-
tained resting M0 macrophages (rM0) were activated to
the M1 phenotype by adding 20 ng/ml IFN-γ (Sigma-Al-
drich Chemie GmbH, Steinheim, Germany) and 500 ng/ml
LPS (Sigma-Aldrich Chemie GmbH, Steinheim, Germany)
to the fresh culture medium for 2 days.
Co-cultivation of osteoarthritic chondrocytes and M1
macrophages
For the co-culture system, THP-1 cells were seeded onto
cell culture inserts (0.6 × 105 cells/Thincert™ cell culture
insert, Greiner Bio-one, Kremsmuenster, Austria) for 6-
well plates and differentiated to rM0 as described above.
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During differentiation process osteoarthritic chondro-
cytes were seeded onto 6-well plates before the co-
cultivation was started by adding 10 % PBS or 10 % of a
1.0 mg/ml HA solution to the culture medium of the
chondrocytes and activate the rM0 to the M1 subtype.
Isolation and cultivation of human osteoarthritic
chondrocytes
Human articular cartilage was received from the University
Hospital Krems from 10 osteoarthritis patients undergoing
total knee arthroplasty. Because of low cell numbers in
most of the cartilage samples, only 3 patients (2 female, 1
male) which had an average of 67 years, approximately 75
to 85 kg and an average height of 180 cm could be used in
the study. The patients were suffering osteoarthritis since 1
to 6 years and were treated by infiltration of the knee and
Cortison or hyaluronic acid. In all cases informed consent
was obtained, and the study was approved by the Regional
Ethical Committee (GS4-EK-4/199-2013).
For chondrocyte isolation, articular cartilage was
minced into 2 mm3 pieces prior to enzymatic digestion
with Liberase TM (0.2 WU/ml, Roche Diagnostics
GmbH, Mannheim, Germany) in medium (GIBCO®
DMEM/F12 GlutaMAX ™-I, Invitrogen, LifeTech Austria,
Vienna, Austria) with antibiotics (penicillin 200 U/ml;
streptomycin 0.2 mg/ml and Amphotericin B 2.5 μg/ml
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany))
under permanent agitation for 18–22 h at 37 °C. The
resulting chondrocyte suspension was passed through a
Cell Strainer with 40 μm pores (BD, Franklin Lakes, NJ)
to remove undigested debris, washed with phosphate-
buffered saline (PBS), centrifuged (10 min, 500 g, room
temperature [RT]) and resuspended in growth medium
(i.e. medium supplemented with antibiotics (see above),
10 % FCS (PAA Laboratories GmbH, Linz, Austria) and
0.05 mg/ml ascorbic acid (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany)). Viability was deter-
mined via trypan blue (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany) staining and cells were counted
using a hemocytometer.
The isolated cells were seeded in growth medium in
75 cm2 culture flasks (Nunc, Rochester, NY) at a density
of 1×104 cells/cm2 and cultivated at 37 °C in a humidi-
fied environment with 5 % CO2. The medium was chan-
ged every 2 to 3 days till 80 % confluency. After
expansion, cells were harvested by the use of accutase
(1.5 ml/flask; PAA Laboratories GmbH, Linz, Austria),
counted and seeded in 6-well plates at a density of
1×104 cells/cm2 (P1 cells).
Flow cytometry
The expression levels of CD14 in the THP-1 cell line, rest-
ing M0 and M1 macrophages were assessed using flow cy-
tometry (FC). For FC, 2 × 105 cells were detached, fixed,
incubated with IgG from human serum (Sigma-Aldrich
Chemie GmbH, Steinheim, Germany) for 20 mins
followed by incubation with anti-CD14 FITC mouse
monoclonal antibody for 45 mins at room temperature in
dark and washed twice with PBS. Flow cytometry analyzes
were performed on samples using the Flow cytometer
FC500 (Beckman Coulter, Brea, CA, USA).
Quantification of proteins
The stored supernatants from THP-1 derived M1 mac-
rophages and osteoarthritic Chondrocytes were analyzed
for the level of cytokines. Cytokines including IL-1β, IL-
6, and TNF-α were measured with Bio-Plex Pro Assays
(BIO-RAD Laboratories, Inc., Hercules, CA, USA). In
this human cytokine multiplex assay, antibodies are cova-
lently coupled to magnetic beads with a unique fluores-
cent dye. Thereby the determination of concentrations of
each analyte using the Bio-Plex 200 analyzer (BIO-RAD)
is possible. For the purpose of analysis, values below the
lower limit of detection for each analyte were recorded as
the lower limit of quantification (LLOQ).
Total-RNA isolation and reverse transcription
For gene expression analysis of THP-1 derived M1 mac-
rophages and osteoarthritic Chondrocytes, the total-
RNA from 6-Well-plates was extracted using the High
Pure RNA Isolation Kit (Roche Diagnostics GmbH,
Mannheim, Germany) in accordance with the manufac-
turer’s protocol. Complementary DNA (cDNA) was syn-
thesized with 1st Strand cDNA Synthesis Kit for RT-PCR
AMV (Roche Diagnostics GmbH, Mannheim, Germany)
and Random Primer p(dN)6 according to the supplier’s in-
struction. cDNA was stored at −20 °C until it was used for
real-time PCR.
Quantitative reverse transcriptase-polymerase chain reac-
tion "RT-qPCR"
Dual labeled probe-based RT-qPCR was performed with
FastStart TaqMan® Probe Master (Roche Diagnostics
GmbH, Mannheim, Germany) and with gene-specific
primers (Eurofins MWG Synthesis GmbH, Ebersberg,
Germany) in triplicate on the iCycler iQ (Bio-Rad Labora-
tories, Hercules, CA). Probes and primers were selected
by use of Universal Probe Library System and by applying
in silico PCR (Roche). The primer-dependent optimal
annealing temperature was determined experimentally.
RT-qPCR was carried out as follows: initial denaturation
step at 95 °C for 10 minutes, further denaturation at 95 °C
for 30 seconds, an annealing step at 55 °C to 62 °C
optimized for the respective primers (Table 1) for 30
seconds, a polymerization step at 72 °C for 15 seconds.
The data resulting from the fluorescence measurement
were relatively quantified without efficiency correction
with R = 2 – ΔCt [MEAN target-MEAN reference] method [14].
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Statistical analysis
Each experiment was performed in triplicate. Data
values are reported as the mean ± standard deviation.
Statistical analysis was performed using ANOVA with a
confidence level of 95 % or more.
Results and discussion
Establishment of the in vitro inflammation model
While complex in vitro inflammation models do exist for
other inflammatory diseases (e.g. bowel disease or diabetic
nephropathy) [15, 16], there is no simple and readily avail-
able osteoarthritis model. Hence, our first objective was to
establish an easy, yet meaningful in vitro inflammatory
osteoarthritis model, composed of differentiated pro-
inflammatory macrophages and human osteoarthritic
chondrocytes. Since primary tissue macrophages cannot
be readily expanded ex vivo, THP-1 monocytic cell line
was initially used to establish an inflammation model with
a more resembled phenotype of human monocyte-derived
macrophages (MDM), which were then differentiated to
the M1 macrophage subtype. After successful differenti-
ation, the inflammation model was used in a co-culture
system to evaluate the influence of pro-inflammatory M1
macrophages on osteoarthritic chondrocytes and the
addition of high-molecular-weight hyaluronic acid, as it
can act as an anti-inflammatory mediator.
The differentiation process of the THP-1 cell line to
resting M0 macrophages (rM0) was based on Daigenault
et al., 2010, since this results in a phenotype that is more
similar to monocyte-derived-macrophages (MDM). The
successful differentiation was demonstrated by the ex-
pression of the specific surface marker CD14. In THP-1
cells 16 % were CD14 positive, while after PMA treat-
ment 74 % of the cells (resting M0 macrophages) had an
expression of the surface marker CD14. For establish-
ment of the inflammation model, differentiated rM0
were activated to the pro-inflammatory macrophage sub-
type M1. To confirm this activation, different parameters
of rM0 and M1 were analyzed. Decrease in CD14 surface
marker expression is a well-described phenomenon with
pro-inflammatory M1 macrophages compared to rM0.
However, flow cytometry analysis revealed that only 38 %
of the M1 macrophages were CD14 positive (Fig. 1a).
Further evaluation showed a significantly higher release
of IL-1β, TNF-α, and IL-6 pro-inflammatory cytokines in
activated M1 macrophages, compared to rM0, where no
or much less inflammatory cytokines were secreted into
the culture medium (Fig. 1c). To verify and confirm this
phenomenon, we also have added an anti-inflammatory
glucocorticoid “dexamethasone” to the M1 macrophage
culture, which should reverse or even stop the release of
pro-inflammatory cytokines from M1 macrophages into
the medium. Veritably, the addition of 1 μg/ml dexa-
methasone to the activation media resulted in a significant
reduction of pro-inflammatory cytokine release of M1
macrophages, which was not significantly different to the
values in the control group (rM0) (Fig. 1c).
Also, a notable upregulation of M1 macrophage-
specific genes (i.e. MMP9 and iNOS) is detectable in in-
flammatory processes [17–19]. We hence evaluated the
expression of these two genes in rM0 and M1 macro-
phages (with or without the addition of dexamethasone).
Gene expression analysis revealed a significant increase
in both genes examined, where MMP9 and iNOS were
both significantly increased in M1, compared to rM0
and the anti-inflammatory group, where dexamethasone
was added to the activation media. As expected, the rela-
tive gene expression in the anti-inflammatory group was
reduced 2-fold for MMP9 or 10- to 20-fold for iNOS
(Fig. 1c). The above results confirm the successful in
vitro differentiation of THP-1 monocyte-derived cells
into pro-inflammatory M1 macrophages.
Establishment of reliable in vitro M1 macrophage and
human osteoarthritic chondrocyte co-culture system
To determine the optimal culture conditions some pre-
liminary experiments were performed to find the most
Table 1 Sequences of Primers and conditions used in
quantitative reverse transcriptase-polymerase chain reaction (RT-
qPCR)
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appropriate cell seeding density of M1 macrophages in
the Transwell™ inserts. Also, the volume of media was
optimized to balance the release of cytokines throughout
the Transwell™ system to have an influence on the
chondrocytes.
Presence of high-molecular-weight hyaluronic acid reduces
pro-inflammatory cytokine secretion from human osteoarthritic
chondrocytes
The implication of hyaluronic acid (HA) as an anti-
inflammatory agent in inflammatory diseases has been
proposed and investigated in in vitro and in vivo condi-
tions [20]. We intended to evaluate the role of high-
molecular-weight (high-MW) HA on the inflammatory
response on human osteoarthritic chondrocytes in our
established in vitro co-culture system (Fig. 2a). Our re-
sults have shown that incubation of OA chondrocytes
with high-MW HA (1600 kDa) leads to a reduced con-
centration of secreted IL-1ß and TNF-α cytokines into
the medium, compared to the control group (Fig. 2b).
We also observed a trend towards a lower concentration
of secreted IL-6 for the HA-treated group, which how-
ever did not reach statistical significance. The above
results possibly suggest the anti-inflammatory properties
of high-MW HA or a potential activation of anti-
inflammatory mechanisms in human OA chondrocytes.
High-molecular-weight hyaluronic acid increases anabolic
and reduces catabolic processes in human osteoarthritic
chondrocytes
Anabolic and catabolic processes are significantly af-
fected in osteoarthritis. In cartilage anabolic processes
are marked by the presence of collagen II (COL2A1) and
aggrecan (ACAN), which are major constituents of hya-
line cartilage. Major markers of catabolism in OA cartil-
age are MMP13 and MMP3, which are known to be
elevated. We hence intended to evaluate the effect of
high-MW HA on these processes in human OA derived
chondrocytes. Our results have revealed that the gene
expression of COL2A1 was significantly increased by
treating OA chondrocytes with high-MW HA in our
established co-culture system (Fig. 3a). ACAN was also
increased, however, did not reach statistical significance.
On the other hand, catabolic mediators like matrix-
degrading enzymes (i.e. MMP13 and MMP3) were de-
creased by adding the high-MW HA to the culture
media, where the difference for MMP3 was even
Fig. 1 Establishment and verification of a functional in vitro macrophage inflammatory model. a Verification of the differentiation from THP-1 cells
to resting M0 macrophages (rM0) and proinflammatory M1 macrophages via flow cytometry analysis of CD14 cell surface expression. b
Representative RT-qPCR gene expression of M1-specific macrophage genes in rM0 and M1 macrophages (with or without the addition of
the anti-inflammatory glucocorticoid dexamethasone (Dex)). c Analysis of secreted pro-inflammatory cytokines into the supernatant after
rM0 and M1 culture (with or without the addition of the anti-inflammatory glucocorticoid dexamethasone (Dex))
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significant. Also, the positive effect of the used HA was
also reflected by the gene expression of COL1A1, as it
decreased by 3-fold compared to the control group. As a
result, the differentiation index (ratio of COL2A1 to
COL1A1) was significantly increased in the HA-treated
group (Fig. 3b).
Despite the availability of several treatment options
and surgical approaches to tackle osteoarthritis (OA),
complications and side effects are still common among
affected individuals [1, 2, 21–23]. Among several alter-
ations in OA, such as inflammatory and biomechanical
properties of cartilage, the reduction in lubricative prop-
erties of the synovial fluid, as well as its constituents (i.e.
hyaluronic acid (HA)) are important factors [22, 24].
Preliminary observation and evaluation of conventional
approaches, like intra-articular viscosupplemental injec-
tions of HA have shown some convincing benefit and
anti-inflammatory potential over the past years in both
animal and human subjects [13, 20, 22, 24–27]. In this
study, we examined the anti-inflammatory, pro-anabolic
and anti-catabolic properties of high-MW HA on human
derived OA chondrocytes in an established and optimized
in vitro pro-inflammatory macrophage co-culture model.
In vitro inflammatory models are useful preliminary ap-
proaches to evaluate pharmacological or other biological
agents before being tested on animals or in other in vivo
conditions. Commonly existing in vitro inflammation
models includes lung [28], intestine [29], brain [30], skin
[31], but for OA, no simple, reproducible and easy handle
in vitro inflammation model does exist. To study the bio-
logical effects of HA on human OA chondrocytes, we first
established and optimized an in vitro inflammatory
macrophage-human OA chondrocyte co-culture model.
We chose the pro-inflammatory M1 macrophage and hu-
man OA chondrocytes in vitro transwell co-culture to be
most appropriate, as it closely resembles the permeable
synovial joint. The successful isolation of primary macro-
phages is difficult and not very reliable. Hence, we adapted
our protocol based on Daigenault et al., 2010 in obtaining
differentiated and activated pro-inflammatory M1 macro-
phages from human monocyte-derived THP-1 cell line
[32]. We also characterized the successful differentiation
process of the THP-1 cells to rM0 or pro-inflammatory
M1 macrophages by flow cytometry and cytokine assay,
utilizing the cell surface marker CD14 (Fig. 1a) and pro-
inflammatory cytokines. We observed a much higher cell
surface expression of CD14 in the resulting rM0
phenotype when THP-1 cells were treated with PMA,
as it is described in literature [33]. Further differenti-
ation with IFN-γ and LPS lead to a decrease in this
Fig. 2 Effect of hyaluronic acid on pro-inflammatory cytokine secretion. a Schematic drawing of the in vitro inflammatory co-culture setup
of differentiated monolayer M1 macrophages on the top and human monolayer osteoarthritic (OA) chondrocytes at the bottom. b Quantification of
pro-inflammatory cytokine concentration in culture medium in the presence or absence of hyaluronic acid
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surface marker, indicating a favorable differentiation
towards M1 (Fig. 1a). These are well described phe-
nomena. Several studies have shown that activated
M1 macrophages secrete pro-inflammatory cytokines,
like IL-1ß, TNF-α, and IL-6 [34, 35]. The presence of
these cytokines is a commonly observed phenomenon
in OA [24, 36, 37] and does closely mimic OA conditions
in our established inflammation model. To further con-
firm the differentiation status of M1 macrophages, we
treated differentiated M1 macrophages with the anti-
inflammatory glucocorticoid agent dexamethasone, which
suppresses the inflammatory response [38]. Indeed, we ob-
served a significantly higher secretion of IL-1ß, TNF-α,
and IL-6 from M1 macrophages that being further sup-
pressed in the presence of dexamethasone, compared to
resting M0 macrophages (Fig. 1c). It should also be noted
that CD14 is a widely used marker for monocyte-
macrophage differentiation [33]. But still some studies re-
port a variation in the response of PMA to THP-1, as
there is an increased CD14 level [39–41] or poor to no re-
sponse [42]., The production of pro-inflammatory cyto-
kines was used to confirm the presence of differentiated
and activated M1 macrophages. The above data presents a
robust and repeatable inflammatory model, consisting of
differentiated pro-inflammatory M1 macrophages. To
closely simulate the permeable OA synovial joint, we have
optimized co-culture conditions of differentiated M1 mac-
rophages, and human derived OA chondrocytes, utilizing
the Transwell™ system. Hyaluronic acid (HA) is a major
component of extracellular matrix (ECM), which is
present in almost all tissues [20]. The different roles of
HA are highly dependent on its molecular weight [43]. In
the healthy joint, HA is an essential synovial fluid con-
stituent with a high-molecular-weight (>1000 kDa) and
moderate ionicity [44]. Besides anti-inflammatory charac-
teristics (i.e. reduced prostaglandin release [45] and re-
duced oxidative stress [46]), it contributes to elasticity and
viscosity of the synovial fluid, shock absorption and cartil-
age ECM structural and functional integrity [22]. HA ex-
ists as a polymer of various chain lengths and different
crosslinking, but previous experiments indicate that HA
molecular weights of 700–6000 kDa are best suited for
cartilage repair [13, 44]. Despite the fact that low-MW
(>10 kDa) HA has appropriate viscoelasticity, moisture re-
tention, and adhesive properties, high-MW HA is used in
clinical practice [13]. Many different HA preparations are
commercially available in Europe and the USA, derived
from different sources, with different molecular weights,
joint residence time and rheological properties [47]. Due
to the reasons explained above, we have evaluated the
effect of high-MW HA on pro-inflammatory cytokine se-
cretion and catabolic, as well as anabolic cartilage markers
Fig. 3 Effect of hyaluronic acid on gene expression in human osteoarthritic chondrocytes. a Representative RT-qPCR gene expression of anabolic
and catabolic cartilage markers in human osteoarthritic monolayer chondrocytes in the co-culture system, with or without the addition of hyaluronic
acid. b Comparative differentiation index between collagen type II and collagen type I in human osteoarthritic monolayer chondrocytes
in the co-culture system, with or without the addition of hyaluronic acid
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in cultured human OA chondrocytes, present in our
established transwell co-culture (Fig. 2a). Our results
have shown a significantly reduced secretion of pro-
inflammatory IL-1ß and TNF-α cytokines, but not IL-6 in
the HA-treated group, compared to the control group
(Fig. 2b). Also, high-MW HA treatment of human OA
chondrocytes in our co-culture system resulted in an in-
creased gene expression of anabolic cartilage markers
(i.e. COL2A1 and ACAN) and reduced catabolic car-
tilage markers (i.e. MMP13 and MMP3), compared to
the control group (Fig. 3a). Chondrocytes tend to de-
differentiate in prolonged 2D cultures, marked by fi-
broblastic morphology and the expression of collagen
type I (COL1A1) [48, 49]. In our transwell co-culture,
we observed a significant reduction of COL1A1 gene
expression (Fig. 3a) and a significant increase in
COL2A1/COL1A1 differentiation index in high-MW
HA-treated human OA chondrocytes, compared to the
non-treated control group (Fig. 3b). Our study confirms
the beneficial effects of high-MW HA in previously
reported in vitro and in vivo studies. Further, this study
confirmed and strengthened previously reported anti-
inflammatory, anti–catabolic and pro-anabolic properties
of high-MW HA in OA chondrocytes and cartilage
[13, 22, 24–27]. The role of HA and his fragments
has been described for several biological processes (i.e. in-
flammation) and clinical conditions, but very limited in-
formation is available for HA in OA chondrocytes [50].
There is increasing evidence that HA fragmentation
through inflammatory induction of hyaluronidases leads
to worsening conditions in OA [44]. The inhibitory activ-
ity of high-MW HA on the secretion of pro-inflammatory
cytokines (i.e. IL-1ß, TNF-α), MMP gene expression
(i.e. MMP13 and MMP3) and no significant change in
IL-6 expression, as observed in our study, is consist-
ent with previously published results.
Conclusions
This study evaluated the anti-inflammatory, catabolic
and anabolic properties of high-MW HA in a robust in
vitro transwell co-culture, containing differentiated pro-
inflammatory M1 macrophages and human derived OA
chondrocytes. Similar to previous studies, we observed a
significant reduction in pro-inflammatory cytokine se-
cretion and catabolic cartilage markers, as well as a stat-
istical increase of anabolic cartilage markers and
COL2A1/COL1A1 differentiation index. Finally, the re-
sults obtained from in vitro models, as in our setting,
should be treated with extreme caution and vigorously
confirmed with subsequent complex follow-up in vivo
experiments, before being applied in the treatment
praxis. Often, it is very hard for practical reasons to re-
produce the simultaneous full scope and cellular constit-
uents of OA disease state in vitro. Hence, most in vitro
OA models are designed to focus on the late disease
stages with a substantial limitation in the evaluation of
disease mechanisms during early stages that may be cru-
cial in targeting that disease.
Abbreviations
ACAN: Aggrecan; CD14: Cluster of differentiation 14; cDNA: Complementary
DNA; COL1A1: Collagen 1; COL2A1: Collagen 2; DMARDs: Disease-modifying
anti-rheumatic drugs; HA: Hyaluronic acid; IL-1β: Interleukin-1 beta; IL-
6: Interleukin-6; iNOS: Inducible nitric oxide synthase; LPS: Lipopolysaccharide;
MDM: Monocyte-derived-macrophages; MMP: Matrix Metalloproteinases;
NSAIDs: Non-steroidal anti-inflammatory drugs; OA: Osteoarthritis;
PBS: Phosphate buffered saline; PCR: Polymerase chain reaction; rM0: Resting
M0 macrophages; TNF-α: Tumor necrosis factor alpha
Acknowledgments
The authors would like to acknowledge the Austrian Research Promotion
Agency (FFG, grant 836432) and Croma Pharma GmbH Austria for supporting
this study.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Authors’ contributions
SN, ENM, and CB acquired funding for this research. CB, ENM, and DK
contributed to the conception and design of the study and acquired data.
CB, ENM, DK, VJ, and SN contributed to the analysis and interpretation of
these data. CB, VJ, SSS, and SN drafted the manuscript. All authors reviewed,
revised, and provided final approval of this manuscript before submission.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical approval for this study was obtained from the Regional Ethical
Committee (GS4-EK-4/203-2013).
Written informed consent was obtained from all subjects before the study.
Received: 4 February 2016 Accepted: 7 September 2016
References
1. Patel S, Dhillon MS, Sundman EA, Cole BJ, Karas V, Della Valle C, Tetreault
MW, Mohammed HO, Fortier LA. The anti-inflammatory and matrix
restorative mechanisms of platelet-rich plasma in osteoarthritis: letter to the
editor. Am J Sports Med. 2014;42:NP30–1.
2. Oliviero F, Ramonda R, Punzi L. New horizons in osteoarthritis. Swiss Med
Wkly Off J Swiss Soc Infect Dis Swiss Soc Intern Med Swiss Soc Pneumol.
2010;140:w13098.
3. Houard X, Goldring MB, Berenbaum F. Homeostatic mechanisms in articular
cartilage and role of inflammation in osteoarthritis. Curr Rheumatol Rep.
2013;15:375.
4. Liu-Bryan R. Synovium and the innate inflammatory network in
osteoarthritis progression topical collection on osteoarthritis. Curr
Rheumatol Rep. 2013;15:1–12.
5. Ishii H, Tanaka H, Katoh K, Nakamura H, Nagashima M, Yoshino S.
Characterization of infiltrating T cells and Th1/Th2-type cytokines in the
synovium of patients with osteoarthritis. Osteoarthr Cartil. 2002;10:277–81.
6. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical
symptoms of osteoarthritis. Nat Rev Rheumatol. 2010;6:625–35.
7. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of
synovial macrophages and macrophage-produced cytokines in driving
aggrecanases, matrix metalloproteinases, and other destructive and
inflammatory responses in osteoarthritis. Arthritis Res Ther. 2006;8:R187.
8. Mimata Y, Kamataki A, Oikawa S, Murakami K, Uzuki M, Shimamura T, Sawai
T. Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like
Bauer et al. Journal of Inflammation  (2016) 13:31 Page 8 of 9
synoviocytes from patients with rheumatoid arthritis. Int J Rheum Dis. 2012;
15:36–44.
9. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J-P, Fahmi H. Role of
proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev
Rheumatol. 2011;7:33–42.
10. Dancevic CM, McCulloch DR. Current and emerging therapeutic strategies
for preventing inflammation and aggrecanase-mediated cartilage
destruction in arthritis. Arthritis Res Ther. 2014;16:429.
11. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the
treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther. 2003;5:
54–67.
12. Albano GD, Bonanno A, Cavalieri L, Ingrassia E, Di Sano C, Siena L, Riccobono L,
Gagliardo R, Profita M. Effect of high, medium, and Low molecular weight
hyaluronan on inflammation and oxidative stress in an in vitro model of
human nasal epithelial cells. Mediators Inflamm. 2016;2016:8727289.
13. Elmorsy S, Funakoshi T, Sasazawa F, Todoh M, Tadano S, Iwasaki N.
Chondroprotective effects of high-molecular-weight cross-linked hyaluronic
acid in a rabbit knee osteoarthritis model. Osteoarthr Cartil. 2014;22:121–7.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods.
2001;25:402–8.
15. Hartman KG, Bortner JD, Falk GW, Yu J, Martin MG, Rustgi AK, Lynch JP.
Modeling inflammation and oxidative stress in gastrointestinal disease
development using novel organotypic culture systems. Stem Cell Res Ther.
2013;4 Suppl 1:S5.
16. Slyne J, Slattery C, McMorrow T, Ryan MP. New developments concerning
the proximal tubule in diabetic nephropathy: in vitro models and
mechanisms. Nephrol Dial Transplant. 2015;30(4):iv60–7.
17. Sindrilaru A, Peters T, Wieschalka S, Baican C, Baican A, Peter H, Hainzl A,
Schatz S, Qi Y, Schlecht A, Weiss JM, Wlaschek M, Sunderkötter C,
Scharffetter-Kochanek K. An unrestrained proinflammatory M1 macrophage
population induced by iron impairs wound healing in humans and mice. J
Clin Invest. 2011;121:985–97.
18. Hanania R, Sun HS, Xu K, Pustylnik S, Jeganathan S, Harrison RE. Classically
activated macrophages use stable microtubules for matrix
metalloproteinase-9 (MMP-9) secretion. J Biol Chem. 2012;287:8468–83.
19. Lepidi S, Kenagy RD, Raines EW, Chiu ES, Chait A, Ross R, Clowes AW. MMP9
production by human monocyte-derived macrophages is decreased on
polymerized type I collagen. J Vasc Surg. 2001;34:1111–8.
20. Ariyoshi W, Okinaga T, Knudson CB, Knudson W, Nishihara T. High molecular
weight hyaluronic acid regulates osteoclast formation by inhibiting receptor
activator of NF-kB ligand through Rho kinase. Osteoarthr Cartil. 2014;22:111–20.
21. Makris EA, Gomoll AH, Malizos KN, Hu JC, Athanasiou KA. Repair and tissue
engineering techniques for articular cartilage. Nat Rev Rheumatol. 2014;11:21.
22. Altman R, Manjoo A, Fierlinger A, Niazi F, Nicholls M. The mechanism of
action for hyaluronic acid treatment in the osteoarthritic knee: a systematic
review. BMC Musculoskelet Disord. 2015;16:321.
23. Fibel KH, Hillstrom HJ, Halpern BC. State-of-the-Art management of knee
osteoarthritis. World J Clin Cases. 2015;3:89–101.
24. Vincent HK, Percival SS, Conrad BP, Seay AN, Montero C, Vincent KR.
Hyaluronic Acid (HA) viscosupplementation on synovial fluid inflammation
in knee osteoarthritis: a pilot study. Open Orthop J. 2013;7:378–84.
25. Edouard P, Rannou F, Coudeyre E. Animal evidence for hyaluronic acid
efficacy in knee trauma injuries. Review of animal-model studies. Phys Ther
Sport. 2013;14:116–23.
26. Migliore A, Procopio S. Effectiveness and utility of hyaluronic acid in
osteoarthritis. Clin Cases Miner Bone Metab. 2015;12:31–3.
27. Ishijima M, Nakamura T, Shimizu K, Hayashi K, Kikuchi H, Soen S, Omori G,
Yamashita T, Uchio Y, Chiba J, Ideno Y, Kubota M, Kurosawa H, Kaneko K.
Intra-articular hyaluronic acid injection versus oral non-steroidal anti-
inflammatory drug for the treatment of knee osteoarthritis: a multi-center,
randomized, open-label, non-inferiority trial. Arthritis Res Ther. 2014;16:R18.
28. Persoz C, Achard S, Leleu C, Momas I, Seta N. An in vitro model to evaluate
the inflammatory response after gaseous formaldehyde exposure of lung
epithelial cells. Toxicol Lett. 2010;195:99–105.
29. Grabinger T, Luks L, Kostadinova F, Zimberlin C, Medema JP, Leist M,
Brunner T. Ex vivo culture of intestinal crypt organoids as a model system
for assessing cell death induction in intestinal epithelial cells and
enteropathy. Cell Death Dis. 2014;5:e1228.
30. Takeshita Y, Ransohoff RM. Inflammatory cell trafficking across the blood–
brain barrier: chemokine regulation and in vitro models. Immunol Rev. 2012;
248:228–39.
31. Magcwebeba T, Riedel S, Swanevelder S, Bouic P, Swart P, Gelderblom W.
Interleukin-1 <math > <mi mathvariant = “bold” > α</mi > </math >
induction in human keratinocytes (HaCaT): an in vitro model for
chemoprevention in skin. J Skin Cancer. 2012;2012:1–10.
32. Daigneault M, Preston JA, Marriott HM, Whyte MKB, Dockrell DH. The
identification of markers of macrophage differentiation in PMA-stimulated
THP-1 cells and monocyte-derived macrophages. PLoS One. 2010;5:e8668.
33. Aldo PB, Craveiro V, Guller S, Mor G. Effect of culture conditions on the
phenotype of THP-1 monocyte cell line. Am J Reprod Immunol. 2013;
70:80–6.
34. Rőszer T. Understanding the mysterious M2 macrophage through activation
markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460.
35. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in
immunity and infectious diseases. Front Immunol. 2014;5(October):1–12.
36. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol.
2011;23:471–8.
37. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick
J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid
arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31:784–8.
38. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive
effects of glucocorticoids, recent developments and mechanistic insights.
Mol Cell Endocrinol. 2011;335:2–13.
39. Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS. Optimized THP-1
differentiation is required for the detection of responses to weak stimuli.
Inflamm Res. 2007;56:45–50.
40. Ding J, Lin L, Hang W, Yan X. Beryllium uptake and related biological effects
studied in THP-1 differentiated macrophages. Metallomics. 2009;1:471–8.
41. Schwende H, Fitzke E, Ambs P, Dieter P. Differences in the state of
differentiation of THP-1 cells induced by phorbol ester and 1,25-
dihydroxyvitamin D3. J Leukoc Biol. 1996;59:555–61.
42. Fleit HB, Kobasiuk CD. The human monocyte-like cell line THP-1 expresses
Fc gamma RI and Fc gamma RII. J Leukoc Biol. 1991;49:556–65.
43. Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a
review. Vet Med (Praha). 2008;53:397–411.
44. Muzzarelli RAA, Greco F, Busilacchi A, Sollazzo V, Gigante A. Chitosan,
hyaluronan and chondroitin sulfate in tissue engineering for cartilage
regeneration: a review. Carbohydr Polym. 2012;89:723–39.
45. Hirota W. Intra-articular injection of hyaluronic acid reduces total amounts
of leukotriene C4, 6-keto-prostaglandin F1alpha, prostaglandin F2alpha and
interleukin-1beta in synovial fluid of patients with internal derangement in
disorders of the temporomandibular j. Br J Oral Maxillofac Surg. 1998;36:35–8.
46. Mongkhon JM, Thach M, Shi Q, Fernandes JC, Fahmi H, Benderdour M.
Sorbitol-modified hyaluronic acid reduces oxidative stress, apoptosis and
mediators of inflammation and catabolism in human osteoarthritic
chondrocytes. Inflamm Res. 2014;63:691–701.
47. Gigante A, Callegari L. The role of intra-articular hyaluronan (Sinovial) in the
treatment of osteoarthritis. Rheumatol Int. 2011;31:427–44.
48. Caron MMJ, Emans PJ, Coolsen MME, Voss L, Surtel DAM, Cremers A, van
Rhijn LW, Welting TJM. Redifferentiation of dedifferentiated human articular
chondrocytes: comparison of 2D and 3D cultures. Osteoarthritis Cartilage.
2012;20:1170–8.
49. Schnabel M, Marlovits S, Eckhoff G, Fichtel I, Gotzen L, Vécsei V, Schlegel J.
Dedifferentiation-associated changes in morphology and gene expression
in primary human articular chondrocytes in cell culture. Osteoarthr Cartil.
2002;10:62–70.
50. Liang J, Jiang D, Noble PW. Hyaluronan as a therapeutic target in human
diseases. Adv Drug Deliv Rev. 2016.
Bauer et al. Journal of Inflammation  (2016) 13:31 Page 9 of 9
